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ABSTRACT
Objective To investigate the effect of vitamin A
supplementation and BCG vaccination at birth in low
birthweight neonates.
Design Randomised, placebo controlled, two by two
factorial trial.
Setting Bissau, Guinea-Bissau.
Participants 1717 low birthweight neonates born at the
national hospital.
InterventionNeonates whoweighed less than 2.5 kgwere
randomly assigned to 25000 IU vitamin A or placebo, as
well as to early BCG vaccine or the usual late BCG vaccine,
and were followed until age 12 months.
Main outcome measureMortality, calculated as mortality
rate ratios (MRRs), after follow-up to 12 months of age for
infants who received vitamin A supplementation
compared with those who received placebo.
Results No interaction was observed between vitamin A
supplementation and BCG vaccine allocation (P=0.73).
Vitamin A supplementation at birth was not significantly
associated with mortality: the MRR of vitamin A
supplementation compared with placebo, controlled for
randomisation to “early BCG” versus “no early BCG” was
1.08 (95% CI 0.79 to 1.47). Stratification by sex revealed
a significant interaction between vitamin A
supplementation and sex (P=0.046), theMRR of vitamin A
supplementationbeing 0.74 (95%CI 0.45 to 1.22) in boys
and 1.42 (95% CI 0.94 to 2.15) in girls. When these data
were combined with data from a complementary trial
among normal birthweight neonates in Guinea-Bissau,
the combined estimate of the effect of neonatal vitamin A
supplementation on mortality was 1.08 (95% CI 0.87 to
1.33); 0.80 (95% CI 0.58 to 1.10) in boys and 1.41 (95%
CI 1.04 to 1.90) in girls (P=0.01 for interaction between
neonatal vitamin A and sex).
Conclusions The combined results of this trial and the
complementary trial among normal birthweight neonates
have now shown that, overall, it would not be beneficial to
implement a neonatal vitamin A supplementation policy
in Guinea-Bissau. Worryingly, the trials show that vitamin
A supplementation at birth can be harmful in girls.
Previous studies and future trials should investigate the
possibility that vitamin A supplementation has sex
differential effects.
Trial registration ClinicalTrials.gov NCT00168610.
INTRODUCTION
Vitamin A deficiency is widespread in low income
countries. Vitamin A supplementation to children
aged 6 months or more has been associated with sig-
nificant reductions in overall mortality.1 To date, six
trials testing the effect of neonatal vitamin A supple-
mentation on mortality have been conducted. Three
trials, all conducted in Asia, have shown that neonatal
vitamin A supplementation has a beneficial effect on
mortality.2-4 Three trials, two conducted in Africa and
one small trial fromNepal, foundnobeneficial effect.5-8
Some groups have advocated that neonatal vitamin A
supplementation be made policy in South Asia.4 9
Other groups, including our own, have found no justi-
fication for initiating comprehensive neonatal vitamin
A supplementation.10-13 As such, an important debate
regarding the potential policy implications is ongoing.
The population of Guinea-Bissau is classified by the
World Health Organization as having moderate to
severevitaminAdeficiency.14 Since2001,Guinea-Bissau
has conducted regular national vitamin A campaigns
during which children between 6 months and 5 years of
age were offered vitamin A supplementation.
We conducted a trial of neonatal vitamin A supple-
mentation trial in Guinea-Bissau in 2002-2005, in
which we randomly assigned newborns of normal
birth weight to receive 50 000 IU vitaminA or placebo
together with the BCG vaccine.7 A total of 27% of the
children in this trial were vitamin A deficient (corre-
sponding to a retinol level below 0.7 μmol/l) at
6 weeks of age and 9% were deficient at 4 months of
age.15 One mother (<1%) was deficient. Neonatal vita-
min A supplementation tended to reduce mortality in
boys; however, it tended to be associated with
increased mortality in girls, particularly when the
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girls started receiving the diphtheria-tetanus-pertussis
(DTP) vaccine recommended at 6, 10, and 14 weeks of
age.16 It has been suggested1718 that the lack of benefit of
vitamin A in our trial could potentially be the result of
the exclusion of low birthweight newborns, because
such children would bemore likely be deficient in vita-
min A than children of normal birth weight. However,
this exclusion criterion would not explain the sex dif-
ferential effects in boys and girls and the fact that the
negative effect in girls coincidedwithDTPvaccination.
In parallel with the trial among normal birthweight
infants, we also conducted a trial among low birth-
weight newborns. Low birthweight infants were ran-
domly allocated in a two by two factorial design to
early BCG vaccination or the usual delayed BCG vac-
cination and to 25 000 IU vitamin A or placebo. We
had hypothesised a priori that vitaminA supplementa-
tion would be particularly beneficial when provided
with the BCG vaccine, but for financial reasons and
owing to the limited number of low birthweight new-
borns, the study was only powered to look for the
effects of vitamin A regardless of BCG allocation.
We found no evidence for interaction between vita-
min A supplementation and BCG vaccination; there-
fore, we chose to present the results of the two
interventions in two separate papers. The “early
BCG” versus “no early BCG” part of the trial will be
presented elsewhere. This paper presents the effects of
neonatal vitamin A supplementation at birth on infant
mortality among low birthweight newborns in urban
Guinea-Bissau. Furthermore, it presents the results of
a combined analysis of the two neonatal vitamin A
trials from Guinea-Bissau.
METHODS
Recruitment
Childrenwere recruited from the study area of theBan-
dim Health Project, which runs a health and demo-
graphic surveillance system in six districts of Bissau,
the capital of Guinea-Bissau. The current population
in these districts is around 102 000, which represents
30% of the inhabitants of the capital. All houses in the
area are visited every month by a project representa-
tive, who registers new pregnancies and births.
Furthermore, all children below 3 years of age are vis-
ited every three months to collect information on vital
status and vaccination status.
Table 1 | Baseline characteristics of low birthweight children who received vitamin A supplementation or placebo at birth
All (n=1717) Boys (n=758) Girls (n=959)
Vitamin A
supplementation
(n=854)
Placebo
(n=863)
Vitamin A
supplementation
(n=362)
Placebo
(n=396)
Vitamin A
supplementation
(n=492)
Placebo
(n=467)
Median maternal mid upper arm circumference
(mm; 10th to 90th centiles)
232
(208 to 274)
232
(206 to 274)
238
(208 to 271)
232
(208 to 274)
232
(208 to 274)
232
(202 to 280)
Median age at enrolment (days; 10th to 90th centiles) 1
(1 to 9)
1
(1 to 9)
2
(1 to 9)
1
(1 to 9)
1
(1 to 9)
1
(1 to 9)
Median Ballard score (10th to 90th centiles) 38
(26 to 42)
38
(27 to 42)
38
(26 to 42)
38
(28 to 42)
38
(27 to 42)
37
(26 to 42)
Median weight at enrolment (kg; 10th to 90th centiles) 2.12
(1.59 to 2.36)
2.16
(1.60 to 2.38)
2.11
(1.63 to 2.36)
2.17
(1.65 to 2.38)
2.14
(1.56 to 2.36)
2.16
(1.52 to 2.38)
Median length (cm; 10th to 90th centiles) 45
(42 to 47)
45
(42 to 47)
45
(42 to 47)
45
(42 to 47)
45
(42 to 47)
45
(42 to 47)
Median mid upper arm circumference
(mm; 10th to 90th centiles)
76
(64 to 88)
76
(64 to 88)
76
(64 to 88)
76
(64 to 88)
76
(64 to 88)
76
(64 to 88)
Median head circumference (cm; 10th to 90th centiles) 30.5
(28.0 to 33.0)
31.0
(28.0 to 33.0)
31.0
(28.0 to 33.0)
31.0
(28.5 to 33.0)
30.5
(28.0 to 32.5)
30.5
(28.0 to 32.5)
Median abdominal circumference
(cm; 10th to 90th centiles)
25.5
(23.0 to 28.0)
25.5
(23.0 to 28.0)
25.5
(23.0 to 28.0)
25.0
(23.0 to 28.0)
25.5
(23.0 to 28.0)
26.0
(23.0 to 28.5)
Had twin or triplet enrolled in the trial (n (%)) 137 (16) 137 (15) 63 (17) 52 (13) 74 (15) 85 (18)
Mother dead at enrolment (n (%)) 5 (1) 1 (0) 2 (1) 0 (0) 3 (1) 1 (0)
From Bandim Health Project study area (n (%)) 214 (25) 196 (23) 94 (26) 89 (22) 120 (24) 107 (23)
Did not receive oral polio vaccine at birth (n (%)) 42 (5) 51 (6) 13 (4) 23 (6) 29 (6) 28 (6)
Allocated to “early BCG” (n (%)) 431 (50) 431 (50) 181 (50) 197 (50) 250 (51) 234 (50)
Invited to participate (n=1737)
Randomly assigned treatment (n=1736)
Placebo (n=872)Vitamin A (n=864)
Placebo (n=863)Vitamin A (n=854)
Refused consent (n=1)
Excluded (n=9):
  Wrong weight (n=9)
Excluded (n=10):
  Wrong weight (n=7)
  Had malformations
    (n=3)
Followed to age
12 months (n=701)
Moved (n=70)
Died (n=83)
Followed to age
12 months (n=710)
Moved (n=75)
Died (n=78)
Fig 1 | Trial profile
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About 3000 children are born in the BandimHealth
Project studyareaeachyear.Theannualnumberof low
birthweight infants identified in the Bandim Health
Project study area, however, is only around 200-300.
To follow a larger groupof lowbirthweight children, in
2002 we initiated recruitment of low birthweight chil-
drenfromotherareasofthecapitalat thematernityward
of the national hospital.
From 27May 2005 to 31 January 2008, all low birth-
weight children born at the national hospital were
offered participation in the two by two factorial trial,
in which they were randomly assigned to early BCG
(intervention group) or postponed BCG according to
local practice (control group), as well as to either
25 000 IU vitamin A (intervention group) or placebo
(control group).
Neonates were identified when they were about to
be discharged. They were investigated by a medical
doctor (BMN),whoascertained that theyhadno severe
malformations and that they were sufficiently well to
be discharged according to local standards. The chil-
dren were weighed on an electronic Seca scale (Seca
GmbH & Co, Hamburg, Germany). If the child
weighed less than 2.5 kg, the assistant at the maternity
ward completed a questionnaire on background fac-
tors. Length was measured on a measuring board,
and arm, head, and abdominal circumferences were
measured with a TALCmid upper arm circumference
tape (Teaching Aids at Low Cost, St Albans, UK) or a
measuring tape. The Ballard score was used to assess
gestational age.
The assistant explained the study tomothers or guar-
dians in the local language (Creole) and provided a
written explanation in the official language (Portu-
guese). If they wished their child to participate, the
mother or guardian was asked to sign a consent form.
Mothers or guardians who could not write their own
name were asked to provide a fingerprint, which the
assistant or the nurse certified.
Intervention
Once consentwas provided, themother drewan envel-
ope from a bag. Each bag was prepared by the study
supervisor and contained 48 envelopes; each envelope
contained a lot name. Within each bag were 12 envel-
opes with lots marked “BCG 6,” 12 marked “BCG 7,”
12 marked “no BCG 6,” and 12 marked “no BCG 7.”
The numbers “6” and “7” indicated from which of two
numbered bottles, “6” or “7,” the child should receive
treatment (that is, either 25 000 IU vitamin A or pla-
cebo). Twins were allocated the same treatment to pre-
vent potential confusion regarding who had been
vaccinated and supplemented. The envelopes were
closed and non-transparent, making it impossible to
identify the allocation before the envelopes were
opened. The result of the randomisation was noted
on the inclusion form and, furthermore, the lot name
was stapled on the form.
Children randomly assigned to “early BCG” were
vaccinated intradermally in the upper left deltoid
regionwith 0.05ml BCG vaccine (Statens Serum Insti-
tut, Copenhagen, Denmark). Children randomly allo-
cated “no early BCG” did not receive a BCG vaccine.
According to usual practice, mothers of children in the
“no early BCG” group were told that their children
should receive a BCGvaccination at a local health cen-
tre when the child had gained weight or when the child
was due to receive the DTP vaccine and the oral polio
vaccine at 6weeks of age (all children shouldbe offered
Table 2 | The effect of vitamin A supplementation at birth on infant mortality
Vitamin A supplementation Placebo
Mortality rate ratio*
(95% CI)Total No
Mortality per 1000 person years
(deaths/person years) Total No
Mortality per 1000 person years
(deaths/person years)
All children 854 110 (83/757) 863 102 (78/762) 1.08 (0.79 to 1.47)
Stratified by BCG vaccination
Randomised to “early BCG” 431 98 (38/386) 431 86 (33/384) 1.14 (0.71 to 1.84)
Randomised to “no early BCG” 423 121 (45/371) 432 119 (45/378) 1.02 (0.67 to 1.56)
Interaction vitamin A supplementation and BCG P=0.73
Stratified by sex
Boys 362 86 (28/325) 394 118 (41/349) 0.74 (0.45 to 1.22)
Girls 492 127 (55/432) 467 89 (37/414) 1.42 (0.94 to 2.15)
Interaction vitamin A supplementation and sex P=0.046
*Adjusted for sex (except for sex stratified analyses) and randomisation to “early BCG” or “no early BCG”.
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Fig 2 | Cumulative mortality during the first year of life for all
children
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oral polio vaccine at birth according to local practice).
Concealing whether a child had received a BCG vac-
cination or not was not possible—the vast majority of
vaccinated children develop a local reaction and sub-
sequently a scar, and the vaccine was noted on the
child’s vaccination card. If we had used a placebo vac-
cine for the “no early BCG” group, some mothers
might have erroneously believed that the child had
received a BCG vaccine and they might not have
sought BCG vaccination later on.
According to the result of the randomisation, children
then received 0.5 ml of oil from either bottle 6 or bottle
7, which was slowly released into themouth of the child
with a sterile syringe by a nurse. The dark glass bottles
used were prepared at Skanderborg Pharmacy, Den-
mark, and all contained 20 doses of 0.5 ml of vegetable
oil. Half of the bottles contained 25000 IU vitaminA as
retinyl palmitate and 10 IU vitamin E per 0.5ml oil; the
other half contained only 10 IUvitaminEper 0.5ml oil.
Apart from the bottle number, the vitamin A and pla-
cebo bottles looked alike. Small differences in the taste
and colour of the contents were judged as unimportant
owing to the recipients’ age. The assistant and the nurse
whowere responsible for the randomisationprocedures
had no ideawhichbottles contained vitaminAorwhich
had placebo when asked. The follow-up assistants were
unaware of the allocated treatment, “6” or “7,” because
they were not present during enrolment and the infor-
mationwas not transferred to the children’s vaccination
card or follow-up forms. The bottles were kept at 5°C,
and a fresh lot was prepared at least once a year. Under
such circumstances, the stability of the retinyl palmitate
is veryhigh.19The codeofwhich treatmentwas inwhich
bottle was kept at the pharmacy until 12 months after
the last child was included. After the trial had ended, a
pair of bottles (one bottle 6 and one bottle 7) were tested
by Vitas Analytical Pharma Services in Oslo, Norway.
The retinol concentration was 56879 IU/ml in one of
the bottles (that is, 28 440 IU per 0.5ml) and 0 IU/ml in
the other bottle.
Follow-up
Thechildrenwere visited at homewithin the first 3 days
of enrolment and at 2, 6, and 12 months of age. To be
able to follow-up the low birthweight children from
outside the study area, we drove the mother and the
newborn child home from the hospital. We then drew
a simple map, registered global positioning system
(GPS) coordinates, and took a photo of the mother
and the house to facilitate subsequent re-identification.
Main outcomes
The main outcome was infant mortality. Deaths were
registered at each visit and the date of death recorded.
When a death had been registered, it was followed up
by a standard verbal autopsy conducted by a trained
local physician at around three months after the death.
The clinician assigned a probable diagnosis on the
basis of the infant’s history.
Routine vitamin A campaigns and vaccinations may
have an impact on the overall results of an inter
vention.20 While this study was being conducted,
there were seven national vitamin A campaigns: in
November 2005, May and November 2006, June and
December 2007, and June 2008 and January 2009.
We collected information on vaccinations at the home
visits. Apart from the home visits, vaccination data
were also collected in case of hospitalisation at the
national paediatric ward. Furthermore, we registered
all vaccinations given daily at the local health centres
in the BandimHealth Project study area, and the vacci-
nation cards of low birthweight children living in the
study area were inspected at the routine home visits
every three months. A two dose measles vaccination
trial that randomly assigned children to an early
measles vaccine at age 4.5 months or to no early
measles vaccine was in progress in the study area at
the same time as the present trial.21 We had measles
Table 3 | Mortality rate ratios according to weight at inclusion
No (%)
All Boys Girls
Vitamin A
supplementation
(n (%))
Placebo
(n (%))
Mortality rate
ratio (95% CI)
Vitamin A
supplementation
(n (%))
Placebo
(n (%))
Mortality rate
ratio (95% CI)
Vitamin A
supplementation
(n (%))
Placebo
(n (%))
Mortality rate
ratio (95% CI)
2.0-2.49 kg 1150 (67) 561 (66) 589 (68) 1.15
(0.74 to 1.80)
235 (65) 276 (70) 0.58
(0.27 to 1.25)
326 (66) 313 (67) 1.74
(0.97 to 3.15)
1.5-1.99 kg 449 (26) 234 (27) 215 (25) 1.05
(0.60 to 1.82)
103 (28) 99 (25) 0.73
(0.32 to 1.68)
131 (27) 116 (25) 1.46
(0.69 to 3.08)
<1.5 kg 118 (7) 59 (7) 59 (7) 0.89
(0.41 to 1.91)
24 (7) 21 (5) 0.90
(0.29 to 2.76)
35 (7) 38 (8) 0.83
(0.30 to 2.27)
*Adjusted for sex (except for sex stratified analyses) and randomisation to “early BCG” or “no early BCG.”
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Fig 3 | Cumulative mortality during the first year of life for boys
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vaccine information of these children at the exact date
of the vaccination.
Determinants suggested by previous studies
Our previous trial of neonatal vitamin A supplementa-
tion in normal birthweight newborns in Guinea-Bissau
showed unexpected interactions that we aimed to test in
the present data set: (1) an interaction between vitamin
A supplementation and season of administration (vita-
min A supplementation had a better effect in the dry
season fromDecember toMay than in the rainy season
from June to November7); and (2) an interaction
between vitamin A supplementation and subsequent
DTP vaccination in girls (afterDTP vaccination, neona-
tal vitamin A supplementation was associated with sig-
nificantly increased mortality in girls16). We also tested
the hypotheses that the effect of vitamin A supplemen-
tation at birth should be particularly beneficial during
the first 48 hours of life22 and that the effect of vitaminA
supplementation at birth varies by weight group.
Combined analysis
We integrated results of the present vitamin A supple-
mentation trial in low birthweight neonates with those
from our complementary trial in normal birthweight
neonates to provide an overall estimate of the effect
of providing neonatal vitamin A in Guinea-Bissau.
Sample size calculations
Assuming a confidence level of 95% and 80% power,
and with an expected infant mortality between day 2
and 12 months of age of 25% among low birthweight
infants, we would need 720 low birthweight infants in
each of the vitamin A and placebo groups to detect a
25% reduction in mortality associated with vitamin A
supplementation. If we were to allow for a 10% loss to
follow-up during the first two months (where there is
high mortality), we would need 800 children in each
group.Oral polio vaccinewasmissing inGuinea-Bissau
during a short period of the trial, and 93 of the study
participants did not receive oral polio vaccine at birth.
Given that we had previously found that oral polio vac-
cineat birthhas strongeffects onmortality,23wedecided
to increase the sample size to 1700 tomake sure that we
had enrolled 1600 children who had all received oral
polio vaccine at birth.
Statistical analyses
All analyses were carried out in Stata 10.0.
Main outcomes
Apriori, our intentionwas to study the effect of neonatal
vitamin A supplementation on overall infant mortality.
We also analysed the effect of vitamin A on survival
from 0-3 months of age, when most previous trials
have found a beneficial effect, and from 4-11 months
of age. Accumulating evidence for sex differential
effects of vitamin A supplementation7162425 made us
hypothesise that vitamin A supplementation would be
particularly beneficial for boys.25
We first analysed the data for interactions between
vitamin A/placebo and “early BCG”/“no early BCG”
allocation. No interaction was found. Owing to the
design, all subsequent analyses of vitamin A effects
were adjusted for “early BCG”/“no early BCG” alloca-
tion. All analyses were also adjusted for sex.
Cumulative mortality curves were calculated using
the Kaplan-Meier estimate based on the date of death
recorded at the first home visit after the death. Differ-
ences in mortality between groups were estimated
using Cox proportional hazards models, with age in
days as the time variable26; therefore, age was inher-
ently controlled for in all analyses. Estimates are
reported asmortality rate ratios (MRRs)with 95% con-
fidence intervals after follow-up to 12months of age for
infants who received vitamin A compared with those
who received placebo. Person years at risk were calcu-
lated from enrolment of infants until they reached
12 months of age, moved, or died. The inter-
dependency of outcomes within twin pairs or triplet
groups was adjusted for by using robust standard
errors. Tests for proportionality of hazard rates were
computed using Schoenfeld’s partial residuals and by
visual inspection of Nelson-Aalen estimators.
Given that any subsequent administration of vitamin
A could neutralise possible differential effects of the
original intervention, we conducted an analysis in
which we censored infants at the date of the first
national vitamin A campaign after they had reached
6 months of age (and were thus eligible for the cam-
paign). Hence, a child born in August 2005 would be
censored at the first day of the national vitamin A cam-
paign in May 2006, and so on.
Determinants suggested by previous studies
We conducted stratified analyses by season, vaccina-
tion status, age at enrolment, and weight group.
Owing to the special policy on BCG vaccination for
low birthweight neonates—that is, that children should
receive a BCG vaccination at a local health centre
when the child had gained weight or when the child
was due to receive the DTP vaccine and the oral
polio vaccine at 6 weeks of age—there was large varia-
tion in the timing and sequence of vaccinations: the
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Fig 4 | Cumulative mortality during the first year of life for girls
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children in our study had 20 different vaccination sta-
tuses during 12 months’ follow-up. Although many
children had received the vaccines in the recom-
mended sequence—that is, BCG before DTP vaccine
—a lot of children also received vaccines out of
sequence—that is, BCGwithDTPvaccine orDTPvac-
cine before BCG. Deviations from the recommended
schedule were more frequent in children outside the
Bandim Health Project study area, where health cen-
tres are not coveredby theBandimHealth Project staff.
All analyses of vaccine status were, therefore, adjusted
for the Bandim Health Project study area.
At 4 weeks of age, only 11% of the children in the
control group had received the BCG vaccination;
therefore,we undertook an analysis of the effect of vita-
min A supplementation by randomisation to “early
BCG” or “no early BCG” at birth in children between
0 and 4 weeks of age. The effect of vitamin A supple-
mentation after DTP vaccination was studied by fol-
lowing up the children from the date of the first
registered DTP vaccination until death, migration,
measles vaccination, or 12 months of age, whichever
came first.
The weight groups were defined as <1.5 kg, 1.5-1.99
kg, and 2-2.49 kg.
Effect modification was analysed by investigating
the homogeneity of the effect of vitamin A supplemen-
tation in the different categories of the suspectedmodi-
fier by using the Wald test.
Combined analysis
The results of the present vitamin A supplementation
trial in low birthweight neonates and those from the
complementary trial in normal birthweight neonates
were pooled using the “meta” command in Stata. A
fixed effects model was used to pool the data because
the heterogeneity tests indicated low degree of hetero-
geneity (all P>0.6).
RESULTS
A total of 1737 children were invited to participate in
this trial, of whom 1736 (99.9%) were randomly
assigned to a study group: 864 to vitamin A supple-
mentation and 872 to placebo (fig 1).
Childrenwere enrolled on the basis of theirweight at
recruitment (less than 2.5 kg); however, 16 children
whoweighed less than 2.5 kg at birth but gainedweight
and weighed 2.5 kg or more at enrolment were erro-
neously randomised. These children were subse-
quently excluded. Three children with malformations
were enrolled in the study; all had been allocated to the
vitamin A group. These infants were also excluded
from the main analysis. Of the 19 children excluded
in total, 10 had been randomly assigned to the vitamin
A group (two children with malformations died, a boy
and a girl) and 9 to the placebo group (none died).
A total of 1717 children were included in the final
study population: 854 who were randomly assigned
to vitamin A supplementation and 863 to placebo.
There were 131 twin pairs and four groups of triplets
in the trial. The baseline characteristics of the vitamin
A supplementation and placebo groups are presented
in table 1.
Main outcomes
A total of 161participants died between enrolment and
their first birthday, which corresponds to a mortality
rate of 106 deaths per 1000 person years, much lower
than the anticipated rate of 250 deaths per 1000 person
years. The mortality rate in infants who received vita-
min A supplementation was 110 deaths per 1000 per-
son years, compared with 102 deaths per 1000 person
years among infants who received placebo (table 2).
Given that the trial was a two by two factorial design,
we first analysed the data for interactions. No inter-
action was found between vitamin A/placebo and
“early BCG”/”no early BCG” allocation (P=0.73;
table 2).
Our analysis controlled for randomisation to “early
BCG” or “no early BCG” showed that vitamin A sup-
plementation at birth was not associated with lower
mortality than placebo (MRR 1.08, 95% CI 0.79 to
1.47; fig 2). The result was unchanged when we
excluded the 93 children who had not received oral
polio vaccine at birth (MRR1.13, 95%CI 0.81 to 1.57).
Stratification by sex revealed a significant inter-
action between vitamin A supplementation and sex:
vitamin A supplementation tended to be beneficial in
boys (MRR 0.74, 95% CI 0.45 to 1.22) but not in girls
(MRR 1.42, 95% CI 0.94 to 2.15; P=0.046 for inter-
action between vitamin A supplementation and sex;
figs 3 and 4).
Vitamin A campaigns
Twelve deaths were excluded when we censored fol-
low-up at the time of the first national vitamin A cam-
paign after the child turned 6 months: six deaths in
children who received vitamin A supplementation
(two boys, four girls) and six deaths in children who
received placebo (three boys, three girls). The overall
MRR for vitamin A supplementation at birth after
these exclusions was 1.08 (95% CI 0.78 to 1.50): 0.75
(95%CI 0.45 to 1.25) in boys and 1.43 (95%CI 0.93 to
2.21) in girls (P=0.06 for interaction).
Cause of death
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Fig 5 | Causes of deaths by intervention group and sex. The “Other problems” category includes
AIDS related deaths, sudden death, tumours, encephalitis, and hepatitis
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Cause of deaths
According to the verbal autopsies, the higher number of
deaths among girls who received vitamin A compared
with girlswho received placebowas due to fever, septicae-
mia, and malaria, as well as malnutrition (fig 5). There
were fewer deaths from respiratory infections, septicae-
mia, and malnutrition in boys who received vitamin A
than in boys who received placebo. No deaths during
the first year of life were caused by accidents.
Determinants suggested by previous studies
Timing of supplementation
VitaminAwas administeredwithin the first 48 hours of
life to 878 (51%) of the 1717 children in the final study
population. The effect of vitamin A on mortality
tended to be negative in children who received supple-
mentationwithin the first 48 hours (MRR1.30, 95%CI
0.82 to 2.05), but beneficial in children who received it
later (MRR0.88, 95%CI 0.57 to 1.37; P=0.23 for inter-
action). The negative effect in children supplemented
within the first 48 hours was seen particularly in girls:
the mortality rate ratio was 2.27 (95% CI 1.19 to 4.31)
for girls supplementedwithin 48 hours, comparedwith
0.94 (95% CI 0.53 to 1.67) for girls supplemented later
(P=0.046 for interaction). The effect estimates were
almost the same when we censored for vitamin A cam-
paigns (data not shown).
Anthropometric status
Enrolment weight and age at supplementation were
strongly associated because we only enrolled children
about to be discharged from thematernityward. The ana-
lysis of timing of vitamin A supplementation was, there-
fore, adjusted for weight group (<1.5 kg (median age at
enrolment nine days), 1.5-1.99 kg (median age at enrol-
ment four days), 2.0-2.49 kg (median age at enrolment
one day); table 3). The effect of vitamin A supplementa-
tion seemed best among the 59 (7%) children who
weighed less than 1.5 kg at enrolment (MRR 0.89, 95%
CI 0.41 to 1.91). Among the two thirds of children who
weighed 2.0 kg or more, vitamin A supplementation was
associated with a 15% higher risk of death (MRR 1.15,
95% CI 0.74 to 1.80). This trend was if anything more
pronouncedwhenwe censored for vitaminA campaigns:
in this situation the negative effect among girls weighing
2.0kgormorewas statistically significant (MRR1.90,95%
CI 1.00 to 3.61; P=0.049).
Season
There was no interaction between vitamin A supple-
mentation and season (data not shown).
Vaccine status
No strong differences in vitamin A supplementation
effects according to BCG status were seen (table 4).
Among children who had received the DTP vaccina-
tion, vitamin A supplementation tended to be asso-
ciated with a slight beneficial effect in boys (MRR
0.66, 95% CI 0.27 to 1.59), whereas the tendency was
the opposite for girls (MRR 1.44, 95% CI 0.75 to 2.78;
P=0.16 for interaction between vitamin A supplemen-
tation and sex). This differential effect was strongest
among the two thirds of children who weighed 2.0 kg
or more at enrolment (MRR 0.57, 95%CI 0.14 to 2.26
for boys and MRR 2.35, 95% CI 0.90 to 6.10 for girls;
P=0.10 for interaction between vitamin A supplemen-
tation and sex).
Combined analysis
When we combined the results from this trial in low
birthweight infants and those from our previous trial
in normal birthweight neonates, overall, neonatal vita-
minA supplementation inGuinea-Bissauwas not asso-
ciated with lower mortality than placebo (MRR 1.08,
95%CI 0.86 to 1.34). Therewas a significant sex differ-
ential effect (MRR 0.80, 95% CI 0.58 to 1.10 in boys
andMRR1.41, 95%CI 1.04 to 1.90 in girls; P=0.01 for
interaction between vitamin A supplementation and
sex; table 5). The P values for homogeneity of vitamin
A effects in the two trials were high (all P>0.60), reflect-
ing the fact that the results of the two trials were similar.
DISCUSSION
Main findings
VitaminA supplementation at birth in low birthweight
neonates born at the national hospital in Bissau,
Guinea-Bissau, did not reduce overall mortality. The
overall result, an 8% increase in infant mortality, was
almost exactly the same as that in our previous trial of
normal birthweight infants.7 It has been suggested that
the lack of beneficial effect of vitamin A supplementa-
tion at birth in our first study was because of the omis-
sion of low birthweight children from the trial.17 18 The
present trial clearly shows that this is not the explana-
tion. Although vitaminA supplementationmay have a
slight beneficial effect among children weighing less
than 1.5 kg, this group represented only 7% of all the
low birthweight children and, therefore, this benefit
had little effect on the overall effect estimate. Among
the slightly heavier children, the effect of vitamin A
supplementation was not beneficial.
As in the previous trial, we found a sex differential
effect of vitamin A supplementation, with a tendency
for a beneficial effect in boys but the opposite in girls.
In the present trial, the interaction between vitamin A
supplementation and sex was statistically significant.
A combined analysis of the two complementary
Guinea-Bissau trials showed very homogeneous vitamin
A effects among low birthweight and normal birthweight
newborns. Although the results of this combined analysis
Table 4 | Mortality rate ratios according to vaccination status and weight at inclusion
Mortality rate ratio* (95% CI)
All Boys Girls
Age 0-4 weeks
Allocated to “early BCG” 1.28 (0.50 to 3.26) 1.67 (0.46 to 6.01) 0.92 (0.23 to 3.68)
Allocated to “no early BCG” 0.98 (0.48 to 1.96) 0.56 (0.20 to 1.59) 1.64 (0.60 to 4.49)
Diphtheria-tetanus-pertussis vaccinated children
All 1.09 (0.65 to 1.82) 0.66 (0.27 to 1.59) 1.44 (0.75 to 2.78)
≥2 kg 1.49 (0.72 to 3.09) 0.57 (0.14 to 2.26) 2.35 (0.90 to 6.10)
<2 kg 0.80 (0.39 to 1.62) 0.70 (0.23 to 2.20) 0.87 (0.34 to 2.22)
*Adjusted for Bandim Health Project study area, sex (except for sex stratified analyses), and randomisation to
“early BCG” or “no early BCG” (analysis of diphtheria-tetanus-pertussis vaccinated children only).
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should be interpreted with caution, they do point towards
a significant sexdifferential effectof vitaminAsupplemen-
tation and a significant negative effect of neonatal vitamin
A supplementation in girls.
Determinants of vitamin A effect
Sex
The present neonatal vitamin A supplementation trial
among low birthweight infants gave surprisingly simi-
lar results to those in our first neonatal vitamin A sup-
plementation trial in normal birthweight infants. The
combined estimate of the effect of vitamin A supple-
mentation on mortality in Guinea-Bissau was 0.80 in
boys and 1.41 in girls. Whereas a mortality reduction
of 20% in boys is by nomeans a small achievement, the
41% significantly increased mortality in girls is worry-
ing. Although the combined analysis of the two sepa-
rate trials cannot be considered equivalent to a single
trial enrolling both low birthweight and normal birth-
weight neonates and randomising them to the same
type of treatment at the same time, it seems clear that
girls in Guinea-Bissau do not benefit from neonatal
vitamin A supplementation.
The very first trial of neonatal vitaminA supplemen-
tation from Indonesia found a borderline significant
sex differential effect2; in the Indian trial, the effect of
vitaminA supplementation was only significantly ben-
eficial in boys.3 So far, the Bangladeshi trial, which had
low coverage for the DTP vaccine, is the only one that
has reported a beneficial effect of vitamin A supple-
mentation on mortality in girls.4
Sex differences in the response to vitamin A supple-
mentation could be due to initial differences in vitamin
A status. In fact, two studies have shown that boys have
lower retinol levels in their cord blood thando girls.27 28
This finding, however, would not explain a negative
effect in girls. We have proposed that the negative
effect of vitamin A and other micronutrients like iron
and zinc onmortality in infant girlsmay be the result of
a negative interaction between immunomodulating
micronutrients and the DTP vaccine, which has been
associated in observational studies with increased
female mortality.29 We need sex stratified data from
the trials in Zimbabwe56 and Nepal 8 to assess whether
the sex differences in response to neonatal vitamin A
supplementation are a more general phenomenon or
related to DTP vaccine coverage.
It is worth emphasising that trials of interventions
rarely examine whether the effect is the same for girls
and boys. In the two trials of vitamin A supplementa-
tion at birth that we have conducted, the overall “no
effect” mortality rate ratio estimate encompasses a
negative effect for girls and a potentially beneficial
effect for boys. By not analysing effects by sex, we
may miss important beneficial effects and also poten-
tially cause harm. Trials in low income countries with
high infant and child mortality should always examine
the intervention for potential sex differential effects.
Vaccine status
As in our previous study, the sex differential effect of
vitamin A supplementation tended to be stronger after
DTP vaccination. The present cohort was small, how-
ever, and the overall influence of DTP vaccination on
the effect of vitaminAonmortality was not statistically
significant.Amonggirlswhoweighed2.0 kgormore at
enrolment, those who received vitamin A supplemen-
tation and theDTP vaccine had twofold highermortal-
ity than those who received the placebo and the DTP
vaccine, as was found in previous studies of the inter-
action between vitamin A supplementation and the
DTP vaccine.16 30-33
Mortalitywasmuchhigher in the small groupof chil-
drenwhoweighed less than 2.0 kg at enrolment. In this
group, therewas no differential effect of vitaminA sup-
plementation among children who had received the
DTP vaccination and those who had not. Presumably
many other “competing” causes of death exist in this
Table 5 | Combined estimates of the effect of vitamin A supplementation on infant mortality in Guinea-Bissau
Mortality rate ratio (95% CI) P for interaction
between vitamin
A and sexAll Boys Girls
Previous normal birthweight trial6
All ages 1.07 (0.79 to 1.44) 0.84 (0.55 to 1.27) 1.39 (0.90 to 2.14) 0.10
0-3 months 1.00 (0.65 to 1.56) 0.94 (0.52 to 1.71) 1.09 (0.56 to 2.11) 0.76
4-11 months 1.13 (0.75 to 1.68) 0.74 (0.41 to 1.34) 1.67 (0.94 to 2.97) 0.05
Present low birthweight trial
All ages 1.08 (0.79 to 1.47) 0.74 (0.45 to 1.22) 1.42 (0.94 to 2.15) 0.05
0-3 months 1.03 (0.69 to 1.53) 0.75 (0.39 to 1.41) 1.29 (0.78 to 2.13) 0.18
4-11 months 1.16 (0.69 to 1.93) 0.73 (0.34 to 1.58) 1.74 (0.84 to 3.63) 0.11
Combined estimates (fixed effects model)
0-11 months 1.08 (0.87 to 1.33) 0.80 (0.58 to 1.10) 1.41 (1.04 to 1.90) 0.01
P for homogeneity of vitamin A effects in the two trials 0.97 0.70 0.94
0-3 months 1.02 (0.76 to 1.36) 0.85 (0.55 to 1.31) 1.21 (0.81 to 1.81) 0.24
P for homogeneity of vitamin A effects in the two trials 0.92 0.61 0.69
4-11 months 1.14 (0.83 to 1.57) 0.74 (0.46 to 1.18) 1.70 (1.08 to 2.67) 0.01
P for homogeneity of vitamin A effects in the two trials 0.94 0.98 0.93
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group and the beneficial effect of vitamin A
supplementation34 may thus outweigh its potential
negative effects. Furthermore, birth weight was a
strong determinant of the likelihood of receiving the
DTP vaccine, and the age of DTP vaccination was
much later among children with the lowest birth
weight (data not shown).
Strengths and weaknesses
The trial was conducted carefully with frequent supervi-
sion at the maternity ward by specially trained staff.
Follow-upwasperformedbyassistantswhowereunaware
of the allocated treatment. As such, there is little reason to
fear information bias with regard to mortality data.
Thepopulation inBissau travels a lot, butwewere able
to followmore than 90%of enrolled participants up until
12 months of age. Loss to follow-up was equally distrib-
uted between the vitamin A and placebo groups.
The information on cause of death was obtained by
verbal autopsy. We were, therefore, only able to cate-
gorise deaths into broad groups, which may be over-
lapping, so the results should be interpreted cautiously.
We conducted many subgroup analyses guided by
results that had been obtained in other trials between
when this trial was designed and its completion. The
results of these subgroup analyses should also be inter-
preted with caution.
Comparison with other studies
Seven trials, including this trial, have studied the effect
of neonatal vitamin A supplementation on mortality.
Three of the four trials from Asia found a beneficial
effect, whereas the three trials from Africa found no
beneficial effect.
It has been proposed that these divergent results could
be due to differences in the prevalence of vitaminA defi-
ciency in the two regions.17 Direct comparisons between
these trials, however, are hampered by the fact that the
trials collected different indicators of vitamin A defi-
ciency. Some results suggest that there was a better effect
of supplementation in areas with vitamin A deficiency;
for example, maternal night blindness seems more pre-
valent in the Asian trials than in the African trials, where
virtually nomothers experiencednight blindness.12Also,
in our trial in Guinea-Bissau, only 9% of normal birth-
weight infants had low vitamin A levels at age
4 months.15 However, children in the Indonesian trial
likewise had a good vitamin A status, but a very good
effect of vitamin A on mortality was reported.2 Also, the
subgroup of 4495 HIV positive women in the Zimbab-
wean trial presumably hadvitaminAdeficiency, yet vita-
min A had no beneficial effect in that group.6
Furthermore, vitamin A supplementation had a signifi-
cant negative effect in the large majority of the children
whowereHIVnegative.Hence, althoughvitaminAsup-
plementation certainly prevents and treats vitamin A
deficiency, it seems that other environmental factors
may modify the effect, making it impossible to predict
outcome on the basis of the pre-existing degree of vita-
min A deficiency alone.
We propose that the divergent results in all these
trials may be explained by differences in vaccination
intensity.12 13 In our experience, neonatal vitamin A
supplementation may have a negative effect on girls
once they receive DTP vaccine.16 If the coverage for
theDTPvaccine is high, the survival curves of children
who receive vitamin A and those who get placebo
should cross over once they start receiving DTP vac-
cine at around 2 months of age. This pattern is seen in
Guinea-Bissau7 and in Zimbabwe,5 which both had
high vaccination coverage.12 Vaccination coverage
was presumably lower in the Asian trials.12 Hence,
existing data are compatible with the hypothesis that
early DTP vaccination might interfere with the benefi-
cial effect of neonatal vitamin A supplementation.
Importantly, a negative interaction of this sort would
have the largest impact in settings where there is high
mortality throughout infancy. In the Asian trials, nearly
all deaths occurred in the first 1-2months of life; as such,
mortality would not be affected by a negative inter-
action between vitamin A supplementation and DTP
vaccine, which is only administered around 2 months
of age. In contrast, theAfrican trials recorded highmor-
tality throughout the 12-24 months of follow-up. “High
neonatal mortality combined with little mortality in the
subsequentmonths”maybebetter than “SouthAsia” as
an indicator of populations inwhichneonatal vitaminA
supplementation may be beneficial.12
Conclusions
In conclusion, the two trials from Guinea-Bissau have
shown that implementing a neonatal vitaminA supple-
mentation policy in the country would not be benefi-
cial overall. Worryingly, vitamin A supplementation
seems to be harmful for girls. Data sets from previous
trials that did not analyse data by sex should undergo a
sex stratified analysis. If it is still considered justified to
conduct studies of vitamin A supplementation at birth
to girls in areas with high infant mortality, further trials
should be designed to investigate the possibility that
vitamin A has sex differential effects.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Six trials of neonatal vitamin A supplementation have shown divergent results with respect to
the impact of supplementation on mortality
Three of the four trials conducted in Asia found a significant beneficial effect of neonatal
vitamin A supplementation, whereas both of the two trials conducted in Africa found no
beneficial effect
The lack of beneficial effect in the African trial from Guinea-Bissau could be to the result of
exclusion of low birthweight neonates
WHAT THIS STUDY ADDS
Neonatal vitamin A supplementation had no overall effect on infant mortality among low
birthweight neonates in Guinea-Bissau
The effect of vitamin A differed significantly by sex: supplementation tended to be beneficial
in boys but not in girls
The significant sex differential effect of vitamin A supplementation remained when the data
from this trial were combined with the complementary trial conducted among normal
birthweight neonates in Guinea-Bissau
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